
Srinivas Viswanathan
@srviswanathan
Physician-scientist | GU oncologist @DanaFarber @Harvardmed. Cancer genomics, functional genetics, RNA | Prostate Cancer; translocation RCC. Opinions my own.
ID: 230237317
http://viswanathanlab.dana-farber.org 24-12-2010 18:09:46
1,1K Tweet
2,2K Takipçi
2,2K Takip Edilen

Congratulations to the Srinivas Viswanathan team! This has been a great collaboration, and I'm super happy to see it out. Featuring two sets of metabolomics data from our core where we confirmed faster turnaround of TCA metabolites in tRCC. nature.com/articles/s4225…

Excited to share our latest work on 5yr outcomes and prognostic value of residual cancer burden with neoadjuvant ADT+ARPI for high-risk prostate cancer, published in European Urology: sciencedirect.com/science/articl… Dana-Farber News Dana-Farber Lank Center for Genitourinary Oncology Adam Kibel Rana McKay, MD, FASCO David Einstein


Stay tuned 📻 for a tweetorial by our rising 🌟Mohammad Jad Moussa, MD, MSc covering our new paper in #kidneycancer

Check out our latest work on MDM2 as a validated target in #gbm. Super collaboration with Veronica Rendo Kalem Lee Sandro Santagata Rameen Beroukhim Patrick Wen and team Kartos Therapeutics and the patients who contributed science.org/doi/10.1126/sc…

1/5 Sharing our Clinical Cancer Research work establishing serum CA-125 as a biomarker for #RenalMedullaryCarcinoma. This is now the first cancer-associated blood biomarker to become standard of care and used globally for a #kidneycancer : aacrjournals.org/clincancerres/… The V Foundation for Cancer Research Chris Johnson Foundation Inc.



We are thrilled to share our March 2025 Postdoc Spotlight, featuring Prathyusha Konda, Ph.D. (Prathyusha Konda ✨) from the Viswanathan Lab (Srinivas Viswanathan)!


📣 Excited to announce the launch of a new patient-partnered research project today – @CountMeIn’s Translocation Renal Cell Carcinoma Project! Delighted to co-PI this project alongside Dr. Elizabeth Mullen ➡️ tRCCproject.org. Dana-Farber Boston Children's Broad Institute

Great time yesterday at the Penn Center for Genome Integrity PCGI Mini Symposium. Thanks for the opportunity to participate!



Our latest study in EMBO Mol. Medicine reveals how TFE3 fusions drive oxidative metabolism and ferroptosis resistance in translocation renal cell carcinoma (tRCC). We define tRCC as a novel metabolic subtype of renal cancer. IGBMC - Srinivas Viswanathan 🔗embopress.org/doi/full/10.10…


We report that Cyclin D1 is an important direct target of HIF2 that drives the proliferation of ccRCC. Our findings further support the notion of combining HIF2 and CDK4/6 inhibitors to enhance antitumor activities. Congrats to Nitin Shirole and the team!


A new study from Damon Runyon Innovator Srinivas Viswanathan takes a closer look at the behavior of the “inactive” X chromosome—and offers a potential explanation for sex-based differences in cancer. Read more: bit.ly/4d2iQRd



